Resilient DSM-Firmenich stock holds in the high €80s as board lines up new chair after FY 2025 earnings

DSM-Firmenich (ISIN CH1216478797) stock is trading in the high €80s on Euronext Amsterdam as of August 18, 2026, with the shares quoted around €87 and showing a mid-single-digit year-to-date gain in the mid-20 percent range according to recent market data.

The company has combined its DSM and Firmenich heritage into a major player in nutrition, health and beauty, and investors are now watching a planned leadership transition at the board level alongside the impact of its latest FY 2025 results on valuation metrics and future growth prospects.

Per an investor update on August 18, 2026, the board of directors has proposed Richard Ridinger as new chair following Thomas Leysen's decision to retire, signaling a move to bring in a successor with extensive industry experience while keeping continuity with the company's strategic path. This governance development arrives shortly after the release of full-year 2025 earnings that showed stable sales but stronger adjusted margins.

Board prepares new chair after Leysen's retirement decision

DSM-Firmenich has announced that Thomas Leysen intends to retire from his role as chair of the board, and the directors are putting forward Richard Ridinger as the proposed successor, subject to shareholder approval in a forthcoming meeting. A Globenewswire release dated August 18, 2026 describes the nomination as part of a planned transition process rather than a sudden change.

For investors, a chair succession can be an important signal for corporate governance and long-term strategy, particularly for a company with a broad global footprint in specialty ingredients and life-science solutions. The proposed appointment of Richard Ridinger, who has held senior roles in the chemicals and life-sciences sectors, suggests a continuation of experienced oversight at the board level while DSM-Firmenich executes on its integration and growth plans.

The leadership news also comes at a time when the share price is trading comfortably below the average analyst target, leaving room for potential re-rating if the new governance structure and operating performance align with expectations. According to recent market data, the average target on DSM-Firmenich is reported at around €91 per share, compared with a last close of €87.50, implying an upside of roughly €3.61 or a mid-single-digit percentage potential if the stock were to move toward that consensus level.

Stock holds in high €80s with double-digit year-to-date gain

On the market side, DSM-Firmenich stock is quoted at €87.12 in real-time trading on Euronext Amsterdam on August 18, 2026, with the previous close at €87.50. MarketScreener price data on August 18, 2026 shows the shares down 0.43 percent on the day but up 26.70 percent since the start of the year, highlighting a strong year-to-date performance despite the modest daily pullback.

Additional quote information from a company overview indicates DSM-Firmenich shares closed at €87.56 in the most recent completed session on the Cboe venue, representing a daily decline of 2.58 percent but still leaving the stock above many levels seen earlier in the year. The same overview underscores that the current price is part of a broader upward trajectory when viewed against the longer-term chart, supported by double-digit percentage gains since January.

Investors who access London-market data see a similar picture: an Euronext-linked quote of €87.44 as of August 18, 2026, with a small 0.14 percent decline over the prior five days, a 7.23 percent drop from a recent intermediate reference level, and a 27.82 percent increase since the start of the year. Group-level data on MarketScreener indicates that despite near-term fluctuations, the broader performance trend for DSM-Firmenich stock has been positive in 2026.

The combination of a roughly €87 trading level, a year-to-date gain in the mid-20s percentage range, and an average target price of €91 provides a clear quantified context: the shares have delivered strong performance so far this year yet still trade a few euros below consensus valuation estimates, which may influence how investors respond to the board's leadership transition and the latest earnings trajectory.

FY 2025 results show stronger adjusted margins on flat sales

Beyond governance and price action, DSM-Firmenich investors are digesting the full-year 2025 results that outline the companys current fundamentals. A detailed FY 2025 financial report published via a newswire release describes how sales for the year came in at €9,034 million compared with €9,054 million in FY 2024, essentially flat with a 0 percent reported change and modest organic growth of 3 percent. The FY 2025 results release therefore positions the top line as broadly stable year-over-year.

Despite the lack of sales growth, DSM-Firmenich managed to improve profitability metrics. Adjusted EBITDA for FY 2025 rose to €1,772 million from €1,751 million in FY 2024, a 1 percent increase that translated into an adjusted EBITDA margin of 19.6 percent, up from 19.3 percent a year earlier. The release also highlights an adjusted EBITDA margin of 19.0 percent in Q4 2025 compared with 18.9 percent in Q4 2024, maintaining a high-teens margin profile even in the final quarter of the year.

On the bottom line, adjusted net profit available to holders of ordinary shares was reported at €528 million in FY 2025 compared with €652 million in FY 2024, reflecting a decrease that likely stems from non-recurring items and integration costs tied to the DSM-Firmenich combination. Basic reported EPS for the year stood at €1.21 versus negative €4.27 in FY 2024, indicating a swing from a loss to a modest profit, while adjusted EPS was €1.94 against €2.41 the prior year.

For investors, the key quantitative comparison is the stability of sales at around €9 billion paired with a slight improvement in adjusted EBITDA-margin percentage and a decline in adjusted net profit and adjusted EPS. The improvement from negative to positive reported EPS year-over-year is a notable turning point, even though the adjusted figures still show that earnings power has not yet fully recovered to the FY 2024 level. This mix of stronger margins but weaker adjusted earnings can feed into ongoing debates about valuation at the current share price around €87 versus the average target of €91 and how much future growth is already priced in.

Q4 2025 trends and guidance context

The FY 2025 release also provides insight into quarterly dynamics. DSM-Firmenich reported Q4 2025 sales of €2,153 million compared with €2,239 million in Q4 2024, a 4 percent decline that suggests some softness in end-year demand or portfolio effects even as the full-year sales level stayed close to flat. The Q4 2025 adjusted EBITDA of €408 million compared with €424 million in Q4 2024 represents a 4 percent decrease, consistent with the lower quarterly revenues but still accompanied by a high-teens adjusted EBITDA margin.

Adjusted EPS in Q4 2025 was €2.08 compared with €2.05 in Q4 2024, indicating a small improvement at the quarterly earnings-per-share level despite the lower top line and adjusted EBITDA. This figure shows that quarterly earnings per share can improve even when revenue declines modestly, thanks to cost discipline, mix effects, and financial items. Investors often look at such quarterly comparisons to assess how sustainable the companys margin profile may be going into the next fiscal year.

While the release contains extensive tables of segment and restated data, the core message is that DSM-Firmenich has achieved a stronger adjusted margin structure with broadly flat sales, and its earnings profile is transitioning from a loss to a modest profit at the reported EPS level. Market participants may interpret this combination as evidence that integration synergies and portfolio optimization efforts are starting to bear fruit, but also that further growth in sales and adjusted EPS will be important in justifying the current share price and the mid-single-digit upside implied by the average target.

Share repurchase program supports capital structure

In parallel with governance changes and earnings, DSM-Firmenich is running a share repurchase program intended to cover share-based plans and reduce capital, which can have implications for per-share metrics and the capital structure. A weekly progress update published on a market-data portal details how the company is buying back shares on Euronext Amsterdam and highlights the impact on ownership and capital reduction over time. The weekly share repurchase report lists execution details and confirms that the program is active as of August 17, 2026.

At a closing price of €87.50 on August 17, 2026, the repurchase program operates at a valuation consistent with the high-€80s trading range and can slowly reduce the number of outstanding shares, thereby supporting EPS and other per-share metrics in future periods if operating performance holds steady or improves. For investors who focus on capital-return policies, the mix of a dividend policy and buybacks often signals management confidence in the companys financial position and cash generation capacity.

Because the repurchase program is framed as both covering employee share plans and reducing capital, it reflects a balance between incentivizing staff and optimizing the capital structure. The timing of the repurchases alongside a board leadership transition and the digestion of FY 2025 results may be interpreted as an effort to maintain steady shareholder returns and offset dilution while the company continues its strategic agenda.

Nutrition, health and beauty portfolio anchors the business

DSM-Firmenichs business is built around a portfolio that spans nutrition, health and beauty, including specialty ingredients, flavors, fragrances and performance solutions for customers in food, beverages, personal care and other sectors. The combination of DSMs historical strengths in vitamins, nutrition and performance materials with Firmenichs expertise in fragrances and flavors is intended to create a diversified, innovation-driven platform.

In practice, this means that DSM-Firmenich can supply customized solutions such as micronutrient premixes for fortified foods, aroma and taste systems for beverages and confectionery, and fragrance compositions for beauty and home care brands. By integrating science-based innovation, regulatory expertise and application know-how, the company positions itself as a partner for customers seeking to improve health outcomes, sensory experiences and sustainability profiles in their products.

Such a portfolio benefits from global consumer trends toward healthier lifestyles, more natural ingredients and differentiated sensory experiences. However, it also means that DSM-Firmenich must continually invest in research and development, regulatory-compliant manufacturing and customer collaboration to stay ahead of competition and meet evolving regulatory and market standards. The FY 2025 margin improvements suggest that the company is managing costs and portfolio mix effectively, but future growth in revenue and adjusted EPS will depend on how successfully it can leverage its combined capabilities.

Representative product example: fragrance and flavor solutions

A representative example of DSM-Firmenichs offering can be found in its fragrance and flavor solutions, where the company develops complex compositions that deliver specific olfactory and taste profiles for brands worldwide. These solutions often combine natural and synthetic ingredients designed to meet regulatory requirements, stability demands and consumer preference trends.

For instance, in beverages, DSM-Firmenich can provide flavor systems that create signature taste experiences in soft drinks, juices or functional drinks, balancing sweetness, acidity and aroma notes. In personal care and home care, its fragrance compositions can help brands differentiate their products through unique scents that align with target demographics and regional preferences. These offerings are supported by sensory research, consumer insights and technology platforms that allow rapid prototyping and scaling.

Because such solutions are customized and embedded in customers end products, they tend to generate recurring revenue streams and long-term relationships. At the same time, they require continuous innovation to keep pace with shifting tastes and regulatory developments, such as demands for more sustainable and transparent ingredients. The business model therefore relies on a combination of scientific expertise, creative talent and supply-chain reliability, all of which can influence margins and competitiveness over time.

DSM-Firmenich stock valuation and investor perspective

At the current trading level around €87 to €87.50, DSM-Firmenich stock reflects a company that has achieved high-teens adjusted EBITDA margins and moved from negative to positive reported EPS between FY 2024 and FY 2025, but still faces the task of lifting adjusted net profit and adjusted EPS back above prior-year levels. The fact that the average target price of €91.11 is only a few euros above the last close suggests that analysts see limited but real upside based on expected improvements in sales growth, integration synergies and continued margin discipline.

For investors, the quantified comparison between the current share price and the average target price, combined with the year-to-date gain of 26.70 percent, underscores that much of the recent improvement in fundamentals and sentiment is already reflected in the valuation. The upcoming board chair transition, ongoing share repurchase program and the companys positioning in nutrition, health and beauty markets are key elements that will influence whether DSM-Firmenich stock can move closer to or beyond the €91 consensus level.

As of August 18, 2026, DSM-Firmenich appears on European exchanges such as Euronext Amsterdam with a robust price performance and a fundamental profile characterized by stable sales, slightly stronger adjusted margins and a shift to positive reported earnings. Investors monitoring the stock will likely track future quarterly results for evidence of renewed top-line growth and further adjusted EPS expansion, while also assessing how the new chair and capital allocation policies shape the companys long-term trajectory.

Go deeper

More on DSM-Firmenich stock

Investor Relations

Product and business model snapshot

DSM-Firmenichs integrated business model revolves around delivering science-backed and creative solutions in nutrition, health and beauty through a combination of ingredient innovation, application expertise and collaborative partnerships with customers across the value chain. By combining DSMs historical strengths in nutritional ingredients, specialty materials and health solutions with Firmenichs leading capabilities in flavors and fragrances, the company aims to provide comprehensive offerings that address functional, sensory and sustainability needs in end products.

This business model is underpinned by global research and development centers, regulatory and scientific teams, and manufacturing sites that can produce high-quality ingredients at scale while complying with stringent food, cosmetic and pharmaceutical standards. It also relies on long-term customer relationships and co-creation initiatives where DSM-Firmenich works with brand owners to develop new products, reformulate existing ones and adapt offerings to local preferences and regulations. The FY 2025 margin results suggest that the company is managing this complex model with increasing efficiency, even as revenue growth remains modest.

Closing view on DSM-Firmenich shares

As of real-time trading on August 18, 2026, DSM-Firmenich shares trade on Euronext Amsterdam at €87.12, slightly below the previous close of €87.50, with a reported year-to-date performance of plus 26.70 percent and an average target price of €91.11 that sits modestly above the current level. This combination of strong year-to-date gains and limited upside to consensus targets frames how investors may weigh governance changes, capital allocation and future earnings momentum when considering DSM-Firmenich stock over the coming quarters.

Fact box

Company: DSM-Firmenich AG

ISIN: CH1216478797

Ticker: DSMF

Exchange: Euronext Amsterdam

Price (as of August 18, 2026, 6:56 a.m. ET): €87.12

Market cap: Data as of latest filings

Sector / Industry: Materials - Specialty chemicals and ingredients

Index membership: Euronext Amsterdam benchmarks